Genome-wide association studies have associated variants in or near the IL33 and the IL-33 receptor (IL33R; also known as ST2 and IL-1RL1) loci with asthma risk.
1-3 IL-33 is constitutively expressed by epithelial and mesenchymal cells in the airway wall and is primarily located in the nucleus at steady state. 4, 5 However, in response to cellular stress, injury, or death, it is released into the extracellular space, where it acts as a cytokine. 6 IL-33 expression is increased in the lungs and airways of patients with asthma and correlates with disease severity. [7] [8] [9] IL-33 levels are also increased in mouse models of asthma, where its blockade is protective. [10] [11] [12] In the context of eosinophilic asthma, IL-33 is pathogenic because it induces type 2 inflammation through expansion and activation of type 2 innate lymphoid cells (ILC2s) and CD4
1 T H 2 cells. These cells produce type 2 cytokines, namely IL-4, IL-5, and IL-13, which act on structural and type 2 effector cells, such as mast cells and eosinophils, to promote the cardinal features of asthma. IL-33 can also directly activate type 2 effector cells and is therefore a central orchestrator of type 2 immunity. Accordingly, several mAbs against IL-33 and its receptor have been developed and have now entered phase I clinical trials. 13 Consistent with an important role in asthma pathogenesis, known asthma triggers, such as allergens and viral respiratory tract infections (most notably respiratory syncytial virus and rhinovirus), induce IL-33 release.
14 Severe viral lower respiratory tract infections in early life, especially in children who later become sensitized to aeroallergens, are a major risk factor for asthma inception, [15] [16] [17] [18] [19] and it is noteworthy that the impaired lung function observed in early life often persists through childhood and into later life, when disease becomes increasingly chronic. 20, 21 To simulate human epidemiology, recently, we developed a preclinical model of asthma by coexposing mice to cockroach allergen and pneumonia virus of mice (PVM), the mouse homologue of respiratory syncytial virus, both in early life to model disease inception and in later life to model disease progression. 22 In this chronic multihit model, antibody-mediated neutralization of IL-33 in early and later life ablated development of the cardinal features of asthma, including airway hyperreactivity, airway inflammation, and airway remodeling. Additionally, we demonstrated that IL-33 acts as a potent suppressor of antiviral immunity, attenuating the induction of type I and III interferons and increasing viral load and thereby predisposing to severe viral bronchiolitis in early life. However, we treated the mice during disease onset in early life, and therefore the effect of IL-33 neutralization on disease progression or established disease, as will be the clinical scenario in which anti-IL-33 treatments are to be directed in the near future, remained unknown.
In a separate mouse model of virus-induced asthma, Sendai virus infection was found to induce an early spike in IL-33 expression followed by a second more intense phase that persisted for several weeks after the virus was cleared, implicating a switch from acute to chronic IL-33 release related to long-lived alterations to epithelial progenitor cells. 23 In light of our recent findings demonstrating a hitherto unrecognized suppressive effect of IL-33 on antiviral immunity, we sought to identify whether IL-33 expression was long-lived in our virus/allergen model. Although it is recognized that the majority of asthma exacerbations in both children and adults are associated with a respiratory rhinovirus infection 24, 25 and that this phenotype is associated with an IL-33-high interferon-low cytokine microenvironment, 14, 26 it is not known whether IL-33 predisposes to the impaired antiviral immunity observed during an exacerbation or as shown in virus-infected primary airway epithelial cells (AECs) from asthmatic patients. 14, 27, 28 Hence we sought to address whether anti-IL-33 therapy would decrease susceptibility to a rhinovirus-mediated acute exacerbation of asthma in a mouse model of chronic asthma on 2 fronts: by decreasing type 2 inflammation and increasing antiviral immunity. To translate our findings, we also analyzed the effect of anti-IL-33 on the antiviral response of human AECs from healthy and asthmatic patients infected with rhinovirus.
METHODS
Detailed methods are available in the Methods section in this article's Online Repository at www.jacionline.org.
Virus and allergen-coinduced asthma and rhinovirus-induced exacerbation
Specific pathogen-free BALB/c mice were inoculated intranasally with PVM (1 plaque-forming unit [pfu] at 7 days old and 20 pfu at 49 days old; strain J3666) 29 and exposed to 1 mg of cockroach extract (CRE) allergen (Greer Laboratories, Lenoir, NC), according to the study design (Fig 1,  A) . 22 
Human bronchial epithelial cell culture
Primary human AECs from healthy subjects and asthmatic patients were obtained from Lonza (Basel, Switzerland). Cells were grown in Bronchial Epithelial Growth Medium (Lonza) and expanded to passage 2 before experimentation. Human AECs were seeded into 24-well plates and grown to 80% confluence before infection with rhinovirus 16 (RV-16) or RV-1B (multiplicity of infection 5 1). RV-16 and RV-1B stocks were generated from infected cultures of HeLa cells, as previously described. 30 After 2 hours, the viral inoculum was removed, replaced with fresh medium, and treated in the absence or presence of anti-IL-33 (1 mg/mL; catalog no. RDSAF3625; R&D Systems, Minneapolis, Minn). At 48 hours after infection, supernatants were removed and snap-frozen, and AECs were collected for RNA isolation (as detailed below).
Flow cytometry
Flow cytometry was performed on bronchoalveolar lavage fluid (BALF) cells or lung tissue digest cells, as previously described. 31 Single-cell suspensions were incubated with fluorochrome-conjugated antibodies (details are provided in the Methods section in this article's Online Repository, gating strategy shown in Fig E7) . Dead cells were excluded when samples were collected with an LSR Fortessa X-20 (BD Biosciences, San Jose, Calif), and data were analyzed with FACSDiva (version 8; BD Biosciences) and FlowJo (version 8.8; TreeStar, Ashland, Ore) software.
Immunohistochemistry
Paraffin-embedded lung sections were prepared, as previously described. 29 Lung sections were stained with anti-IL-33, anti-pro-surfactant protein C (pro-SPC), anti-high-mobility group box 1 (HMGB1), anti-a-smooth muscle actin, and anti-Muc5ac, as detailed in the Methods section in this article's Online Repository.
Measurement of protein expression
Murine IL-33 (R&D Systems), IL-25 (BioLegend, San Diego, Calif), and IL-5 (BD Biosciences) expression was quantified by means of ELISA, and IL-13 (Enhanced Sensitivity Flex Set; BD Biosciences) expression was quantified by using the cytokine bead array. Human IFN-l and IL-33 levels were quantified by means of ELISA (R&D Systems).
Quantitative real-time PCR
Total RNA was isolated with TriReagent solution, followed by phenolchloroform extraction. Reverse transcription was performed with M-MLV reverse transcriptase, and then quantitative real-time PCR was performed by using SYBR Green and the primers described in Table E1 in this article's Online Repository at www.jacionline.org.
Statistical analyses
GraphPad Prism software (version 7.0; GraphPad Software, La Jolla, Calif) was used for all statistical analyses. The Student t test, 1-way ANOVA with the Tukey post hoc test, or 2-way ANOVA with the Sidak post hoc test was applied, as appropriate. A P value of less than .05 was considered statistically significant.
RESULTS
Treatment with anti-IL-33 during the progression and chronic phases reduces many key features of the asthmatic phenotype Previously, we developed a preclinical model of asthma that simulates the synergistic interactions between lower respiratory tract infections and low-dose allergen exposure. 22 Critically, this model (see Fig 1, A, for study design) deliberately uses a low dose of virus and low dose of cockroach allergen that, when administered alone, are not sufficient to induce the hallmark features of asthma. Moreover, we identified that the onset of disease is critically dependent on the timing of virus and allergen coexposure in early life.
Before assessing the effectiveness of anti-IL-33 as a therapeutic, we first wanted to assess whether the timing of the second virus and allergen exposure was critical for disease progression. ) neonatal mice were infected with PVM and exposed to CRE 3 days later. Mice were then reinfected 6 weeks later and exposed to CRE weekly. Mice were treated with anti-IL-33, relevant isotype control, or dexamethasone, as indicated. B and C, Eosinophils (Fig 1, B) and neutrophils (Fig 1, C) in BALF. D-F, ILC2s (Fig 1, D) , CD4 T cells (Fig 1, E) , and T H 2 cells (Fig 1, F) in the lung. G, Mucus production in the lung quantified as a score of Muc5ac expression. H, ASM area. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice. Box and whisker plots show quartiles (boxes) and ranges (whiskers; n 5 5-8 mice per group) representative of 2 experiments. Dex, Dexamethasone; Iso, isotype; Veh, vehicle. *P < .05, **P < .01, and ***P < .001. #P < .05 and ##P < .01. (Fig 2, B) and neutrophils (Fig 2,  C) in BALF. D-F, ILC2s (Fig 2, D) , CD4 T cells (Fig 2, E) , and T H 2 cells (Fig 2, F) in the lung. G, Muc5ac score. H, ASM. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice at that dosing regimen. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 6-8 mice per group representative of 2 experiments. Dex, Dexamethasone; DPI, days postinfection; Iso, isotype; Veh, vehicle. *P < .05, **P < .01, and ***P < .001. #P < .05 and ##P < .01. (Fig 1, A) , which allowed us to test the effectiveness of anti-IL-33 when administered during disease progression or as a therapeutic agent in patients with established disease.
To assess the effectiveness of IL-33 neutralization on disease progression, mice were inoculated with PVM and CRE and then treated intraperitoneally with anti-IL-33 or control isotypematched antibody, starting in the progression phase and continuing through the chronic phase (Fig 1, A) . An additional group of mice was treated with the corticosteroid dexamethasone (75 mg) for comparison with conventional therapy. Mice treated with the isotype control had increased numbers of airway eosinophils and neutrophils coupled with increased levels of ILC2s, total CD4 T cells, and CD4 T H 2 cells (identified by ST-2 expression) 32 compared with mice exposed to vehicle (ie, non-PVM and non-CRE; Fig 1, B-F) . Consistent with our previous findings, 22 production of IL-5 and IL-13 was not detectable 72 hours after challenge (data not shown). However, cellular inflammation was associated with features of airway remodeling, including mucus hypersecretion and increased ASM mass (Fig 1, G and H) . In response to treatment with either anti-IL-33 or dexamethasone, the number of airway eosinophils was significantly decreased compared with that seen in mice treated with the isotype control. In contrast, neither treatment affected neutrophils, lymphocytes, regulatory T cells, mononuclear cells, or total cell counts in BALF (Fig 1, B and C; see Fig  E2 in this article's Online Repository at www.jacionline.org; and data not shown). Both treatments also significantly reduced lung ILC2s and CD4
1 T H 2 cells and mucus hypersecretion (Fig  1, D-G) ; however, only anti-IL-33 prevented the increase in ASM mass (Fig 1, H) .
IL-33 blockade during the chronic phase affects type 2 immunity but not airway remodeling
Mice were treated 24 hours before each of the CRE exposures in the chronic phase (C2-C4) to address the potential effectiveness of anti-IL-33 or dexamethasone in patients with established disease (Fig 2, A) . By using this regimen, neither treatment had (Fig 4, D) , CD4 T cells (Fig 4, E) , and T H 2 cells (Fig 4, F) in the lung. G, Muc5ac score. H and I, IL-13 (Fig 4,  H) and IL-5 (Fig 4, I ) expression in BALF. *Significance compared with vehicle-treated mice. #Significance compared with PVM/CRE/PVM/CRE/RV mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 6-9) representative of 2 experiments. *P < .05 and ***P < .001. #P < .05, ##P < .01, and ###P < .001.
any substantive effect: anti-IL-33 only reduced airway eosinophil and neutrophil numbers (Fig 2, B and C, and see Fig E3 in this article's Online Repository at www.jacionline.org), whereas dexamethasone decreased CD4
1 T H 2 cell counts (although this was not significant; Fig 2, D-F) . We reasoned that the lack of efficacy might relate to a lack of IL-33 coverage and assessed the effect of a twice-weekly dosing regimen. In addition to the parameters affected by the once-weekly dosing, ILC2s, CD4
1 T H 2 cells, and mucus hypersecretion were then also significantly decreased by anti-IL-33, whereas twice-weekly dexamethasone only affected ILC2s in the lung (Fig 2, B-G) . Notably, neither treatment affected ASM growth (Fig 2, H) . Mice were treated twice weekly with anti-IL-33, isotype, or dexamethasone in the 4 weeks before RV-1B infection. B and C, Eosinophils (Fig 5, B) and neutrophils (Fig 5, C) in BALF. D-F, ILC2s (Fig 5, D) , CD4 T cells (Fig 5, E) , and T H 2 cells (Fig 5, F) in the lung. G and H, IL-13 (Fig 5, G) and IL-5 (Fig 5, H) expression in BALF. I, Muc5ac score. J, Cytoplasmic HMGB1 expression in AECs. K, HMGB1 expression in BALF. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice. Data are means 6 SEMs (n 5 7-9 mice per group) representative of 2 experiments. Dex, Dexamethasone; DPI, days postinfection; Iso, isotype; Veh, vehicle. *P < .05, **P < .01, and ***P < .001. #P < .05, ##P < .01, and ###P < .001.
Established respiratory disease induces long-term changes to structural cells of the lung
We next investigated whether the structural alterations would persist in the absence of viral or allergen challenge (Fig 3, A) . As expected, ASM mass remained significantly increased when assessed 4 weeks (day 94) after final CRE exposure (Fig 3, B) . Although the extent of mucus hypersecretion and other measures of type 2 inflammation had resolved (data not shown), the IL-33 concentration in BALF was significantly greater at 94 days after infection than at 69 days after infection. IL-33 (red) was expressed primarily in pro-SPC-positive (green) alveolar epithelial cells in both vehicle-and PVM/CRE-exposed mice; however, the intensity of the IL-33 immunoreactivity was far greater in the mice exposed to PVM/CRE (Fig 3, D) . Recently, we and others have identified that HMGB1, another nuclear alarmin, contributes to the cytokine cascade that amplifies type 2 inflammation. 33, 34 Levels of cytoplasmic HMGB1 in the bronchial epithelium were significantly greater in the mice coexposed to PVM/CRE and remained increased at day 94 (Fig 3, E) , suggesting that the effects of virus/allergen coexposure on airway structural cells are long-lived and persist in the absence of overt cellular inflammation.
Exacerbation with rhinovirus induces type 2 inflammation
In light of the persistent airway remodeling and IL-33 production and also our recent findings that IL-33 suppresses antiviral immunity during disease onset, 22 we postulated that even without a recent allergen exposure, mice with features of chronic asthma would be more susceptible to an acute exacerbation triggered by rhinovirus exposure. To test our hypothesis, healthy (vehicleexposed) and diseased (PVM/CRE coexposed) mice were inoculated 4 weeks after the final CRE challenge with RV-1B (5 3 10 6 TCID 50 ), which, unlike most rhinovirus strains (eg, RV-16), can infect and replicate in mice (Fig 4, A) . 35 Three days after rhinovirus inoculation, both airway eosinophil and neutrophil numbers were significantly increased in the diseased mice compared with those in healthy control mice. Similarly, ILC2 numbers, CD4
1 T H 2 cell numbers, and mucus hypersecretion were significantly greater in diseased mice (Fig 4, B-G , and see Fig E4 in this article's Online Repository at www.jacionline.org). This phenotype was associated with a significant increase in IL-13 and IL-5 levels in BALF (Fig 4, H and I) . Importantly, the hyperinflammatory response to rhinovirus inoculation was not evident in mice that had been exposed to CRE alone, PVM alone, or PVM alone in early life with PVM/CRE coexposure in later life (Fig 4, B-I) . Moreover, rhinovirus inoculation of healthy mice did not induce significant IL-33 or IL-25 release (see Fig E4, A and B) . As expected in the short 3-day timeframe, RV-1B inoculation did not increase ASM mass in any of the treatment groups (data not shown). IL-33 was not detectable in BALF at 1 or 3 days after rhinovirus challenge (data not shown).
Blocking IL-33 before rhinovirus exacerbation decreases type 2 inflammation
This unique preclinical model allowed us to test whether immunoneutralization of IL-33 would decrease the magnitude of type 2 inflammation in response to an acute rhinovirus-induced exacerbation in the setting of chronic asthma. PVM/CREcoexposed mice were treated twice a week with dexamethasone, anti-IL-33, or isotype-matched control in the 4 weeks between the final CRE challenge and the rhinovirus inoculation (Fig 5, A) . Anti-IL-33 significantly attenuated numbers of eosinophils and neutrophils in the airways and ILC2s and CD4
1 T H 2 cells in the lungs compared with those in mice treated with the isotype control (Fig 5, B-F , and see Fig E5 in this article's Online Repository at www.jacionline.org). Treatment with dexamethasone was similarly or more effective at dampening the inflammatory cell response (Fig 5, B-F) , and of note, both treatments decreased the number of CD4 1 T cells in the lungs before the rhinovirus exacerbation (Fig 5, E) . Furthermore, both treatments significantly decreased IL-13 and IL-5 expression in the airways compared with that seen in the isotype-matched treatment group (Fig 5, G and H) . Despite pronounced suppression of type 2 inflammation, only dexamethasone treatment significantly reduced epithelial Muc5ac expression (Fig 5, I) .
Interestingly, however, treatment with anti-IL-33, but not dexamethasone, decreased significantly the fraction of bronchial epithelial cells with cytoplasmic HMGB1 before rhinovirusinduced exacerbation (Fig 5, J) . After rhinovirus infection, expression of cytoplasmic HMGB1 was dramatically diminished, regardless of treatment group, which is suggestive of its extracellular release. When measured in BALF at 1 day after infection, HMGB1 levels were significantly increased in the isotype-or #Significance compared with isotype-treated mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 5-7 mice per group) representative of 2 experiments. Dex, Dexamethasone; DPI, days postinfection; Iso, isotype. *P < .05, **P < .01, and ***P < .001. #P < .05 and ###P < .001.
dexamethasone-treated mice but not in the anti-IL-33-treated mice (Fig 5, K) .
IL-33 blockade before exacerbation boosts antiviral immunity
In light of our previous finding that IL-33 suppresses antiviral immunity during PVM infection in early life, 22 we questioned whether IL-33 affects the host response to rhinovirus infection. It was noteworthy that the viral load in diseased (isotype-treated) mice was significantly greater than that in healthy (naive) mice, which was similar to the delayed clearance observed in rhinovirus-inoculated asthmatic mice (Fig 6, A) . 14, 26 Moreover, this phenotype aligned with an attenuated Ifna response in the lungs (Fig 6, B) . Strikingly, when diseased mice were pretreated with anti-IL-33, the viral load and expression of Ifna, IfnL, and Ifng in the lungs were equivalent to those of healthy mice (Fig 6, B) . In stark contrast, dexamethasone treatment did not decrease viral load and did not modulate interferon gene expression.
Anti-IL-33 increases antiviral immunity in AECs from healthy subjects and asthmatic patients
In light of our findings in mice, we postulated that IL-33 might contribute to the loss of viral control and impaired interferon production observed previously in in vitro-cultured AECs from asthmatic patients. 27, 28, [36] [37] [38] Using human AECs obtained from healthy subjects and asthmatic patients, we confirmed that viral replication (both RV-16 or RV-1B; multiplicity of infection 5 1) was significantly greater in human AECs from asthmatic patients (Fig 7, A and B) . Strikingly, pretreatment with anti-IL-33 significantly decreased RV-16 replication in both cells from healthy subjects and those from asthmatic patients (Fig 7, A) . A similar trend was observed with RV-1B-infected human AECs (Fig 7, B) . RV-16-or RV-1B-induced IFNL gene expression was significantly lower in human AECs from asthmatic patients and was significantly upregulated on pretreatment with anti-IL-33, regardless of disease status (Fig 7, C and D) . At the protein level, RV-16-stimulated IFN-l production was significantly increased from the human AECs of asthmatic patients when IL-33 was neutralized (Fig 7, E and  F) . IFNB gene expression was not significantly different between healthy subjects and asthmatic patients; however, IFNB transcripts were significantly increased after treatment with anti-IL-33 in the asthmatic patients in response to either virus strain (Fig 7, G and H) . Although IL-33 protein was not detectable in the supernatant at 48 hours after infection (see Fig E6 in this article's Online Repository at www.jacionline.org), IL33 mRNA levels were significantly increased after rhinovirus infection (Fig 7, I and J).
DISCUSSION
In this study we used a preclinical mouse model of chronic asthma that simulates the synergistic interplay between viral and allergen exposure and has 4 distinct phases: onset, progression, chronic, and exacerbation. We found that anti-IL-33 treatment during the progression and chronic phases, during the chronic phase alone, or before the exacerbation phase alone attenuated the magnitude of type 2 inflammation and asthma-like pathologies in the airway wall. In general, anti-IL-33 was as effective at ameliorating disease as treatment with the corticosteroid dexamethasone, although there were subtle differences depending on the timing of treatment. However, the most stark difference was observed in the exacerbation phase: although dexamethasone had no effect on antiviral host defense, anti-IL-33 promoted antiviral immunity and decreased viral burden. Importantly, the suppressive effect of IL-33 on antiviral immunity was confirmed in RV-16-or RV-1B-infected human AECs from healthy subjects and asthmatic patients.
Consistent with the findings of others, we observed that IL-33 blockade decreased the cellular inflammation associated with T H 2 immunity, including CD4
1 T H 2 cells, ILC2s, and eosinophils (Figs 1 and 2) . [10] [11] [12] Unfortunately, because of the lungs collapsing during the forced oscillation technique, we could not assess the effect of IL-33 blockade on airway hyperreactivity. However, we recently reported that anti-IL-33 also prevents ASM hyperplasia when administered during the onset and progression of asthma, 22 and we confirm these findings here by showing that treatment during both the progression and chronic phases is similarly effective. However, we also revealed that commencing treatment after the progression phase has no effect on ASM remodeling (Fig 2) . These data are concordant with clinical reports indicating the ASM becomes more fixed and difficult to reverse in asthmatic adults 39, 40 and highlight the need for asthma interventions in early life when the ASM is more amenable to treatment, perhaps as a consequence of greater plasticity.
In the steady state IL-33 is expressed primarily by nonhematopoietic cells, including epithelial (alveolar and bronchiolar) and endothelial cells. 4, 5, 8, 9 We previously reported that PVM/CRE coexposure increases IL-33 expression in bronchial epithelial cells during disease onset 22 ; however, when we assessed IL-33 levels after the progression and chronic phases, we found that IL-33 was expressed primarily by alveolar epithelial cells, even after 4 weeks without an environmental stimulus (Fig 3) . This phenotype was associated with high levels of IL-33 in the airway lumen and was reminiscent of the findings observed in a mouse model of Sendai virus infection, 23 although our model incorporated multiple exposures, which is more typical of disease etiology. In contrast to the Sendai virus model, IL-13 expression, which can feed-forward to amplify IL-33 levels, 41 was not increased. Rather, the phenotype in our model was similar (Fig 7, A) and RV-1B (Fig 7, B ) viral copies were measured by using quantitative PCR. C and D, Gene expression of IFN-l after RV-16 (Fig 7, C) or RV-1B (Fig 7, D) infection. E and F, IFN-l expression in supernatants after RV-16 (Fig 7, E) or RV-1B (Fig 7, F) infection. G and H, Gene expression of IFN-b after RV-16 (Fig 7, G) or RV-1B (Fig 7, H) infection. I and J, IL-33 expression in uninfected (UI) samples and RV-16-infected (Fig 7, I ) or RV-1B-infected (Fig 7, J) human AECs. *Significance within groups. #Significance between cells from healthy subjects and asthmatic patients (n 5 5 patients per group in duplicate). *P < .05. #P < .05 and ##P < .01. ns, Not significant.
=
to that observed in children with severe asthma, who express greater levels of IL-33 in structural cells in the absence of an increased IL-13 signal. 12 Additionally, we identified that the cytoplasmic expression of HMGB1, another alarmin that is constitutively expressed in the nuclei of barrier cells and contributes to type 2 inflammation, 33, 34 remained significantly increased in bronchial epithelial cells long after the final CRE exposure. Further studies are needed to identify the molecular mechanism that leads to the increased and persistent expression of IL-33 and HMGB1 because this might identify a novel target or targets for therapeutic intervention.
Acute asthma exacerbations are a major cause of morbidity and mortality and present a considerable health care burden. Current therapeutic options to manage exacerbations are suboptimal: corticosteroids reduce exacerbations by 50%, 42 anti-IL-5 therapy allows for steroid sparing but again only reduces exacerbations by 50%, 43, 44 and type I interferon therapy does not improve symptoms during a viral exacerbation. 45 More representative and predictive preclinical models of viral exacerbation are required to address this unmet need. 46 Disappointingly, inoculation with rhinovirus shortly after the final allergen challenge in acute models of allergic asthma (using ovalbumin or house dust mite) induces an inflammatory response that is short lived (lasting <24 hours) and predominantly neutrophilic, [47] [48] [49] [50] [51] which is contrary to the clinical phenotype. 14, 26 By contrast, rhinovirus challenge after the chronic phase in our model induced a mixed granulocytic response that was associated with increased numbers of ILC2s and CD4
1 T H 2 cells and a marked increase in type 2 cytokine production (Fig 4) . Importantly, this phenotype was not present in mice that had been exposed to cockroach alone or even mice that had been subjected to all exposures bar the CRE administration in early life. Thus viral bronchiolitis in early life increased susceptibility to a rhinovirus-triggered exacerbation of asthma in later life. The molecular processes that underpin this switch in early life remain elusive; however, the long-lived effects might reflect epigenetic alterations in progenitor epithelial cells and/or immune cell populations and are evidently activated on rhinovirus infection.
In light of the ability of rhinovirus to induce IL-33 release from human bronchial epithelial cells 14 and the increased IL-33 levels in the chronic phase of our model, we hypothesized that neutralization of IL-33 before inoculation with rhinovirus would diminish the severity of the exacerbation. Similar to corticosteroid treatment, anti-IL-33 significantly decreased the magnitude of the type 2 response (eg, eosinophils, ILC2s, and type 2 cytokines) induced in response to rhinovirus challenge (Fig 5) . However, in contrast to the progression and chronic phases, anti-IL-33 did not reduce epithelial Muc5ac expression induced by rhinovirus infection, perhaps because of cytokine redundancy. 52, 53 Both treatments also decreased the number of CD4
1
T cells in the lungs before exacerbation. Interestingly, pretreatment with anti-IL-33, but not dexamethasone, decreased the number of bronchial epithelial cells expressing cytoplasmic HMGB1 before rhinovirus challenge, and as a consequence, the concentration of HMGB1 released into BALF was significantly decreased after the rhinovirus-induced exacerbation. This is important because we and others have shown that HMGB1 is a type 2 instructive cytokine, 33, 34 like IL-33. Alarmins commonly initiate feed-forward mechanisms to amplify innate immunity. 33 Our findings implicate a role for IL-33 in maintaining the dysregulated and proinflammatory epithelium that is now recognized to be a hallmark feature of asthma.
Rhinovirus-stimulated IFN-l and IFN-b production has been shown to be impaired in bronchial epithelial cells from asthmatic or allergic subjects, 27, 28, 54 although other studies did not replicate this phenotype. 55, 56 Intriguingly, in response to experimental rhinovirus infection, viral load was significantly higher and correlated with nasal IL-33 expression in asthmatic patients compared with healthy subjects 14 ; however, whether IL-33 directly caused loss of viral control was not addressed. In our preclinical model antiviral cytokine expression was markedly impaired in diseased compared with healthy mice after rhinovirus inoculation, implicating the existence of a negative regulatory process in diseased mice.
In light of our recent findings demonstrating that IL-33 suppresses antiviral immunity, 22 we postulated that after the chronic phase, persistently increased IL-33 levels would affect host immunity. Consistent with this theory, anti-IL-33 treatment before rhinovirus exacerbation restored production of antiviral cytokines and diminished the level of rhinovirus viral copies to that observed in rhinovirus-inoculated healthy mice (Fig 6) . In contrast, dexamethasone treatment had no effect on viral load or the dampened interferon production, and thus the beneficial effects of dexamethasone on the proinflammatory response appear to be outweighed by their detrimental effect on local antiviral immunity, at least in the short term. Importantly, through immune neutralization of human IL-33, we confirmed that rhinovirusinduced IL-33 dampens antiviral immunity and increases viral replication in human AECs obtained from both healthy subjects and asthmatic patients (Fig 7) . Although IL-33 protein expression was not detectable in the supernatant, possibly because of its degradation, we observed a significant upregulation in IL33 mRNA levels in RV-1B-stimulated human AECs from asthmatic patients.
Taken together, our findings suggest that anti-IL-33 protects against virus-induced exacerbation through 2 mechanisms: decreasing type 2 inflammation and restoring antiviral immunity. Studies are now urgently required in human subjects to confirm the anti-type 2 effects of neutralizing IL-33, but perhaps more importantly, it will be critical to assess whether IL-33 blockade restores antiviral immunity and epithelial homeostasis in vivo because there might be the potential to return the airway epithelium to the healthy steady state.
In conclusion, we present a novel preclinical model of chronic asthma that recapitulates much of the human epidemiology and highlights a critical role for IL-33 in disease progression, chronicity, and exacerbations. IL-33 blockade attenuates type 2 inflammation in all phases of disease, although its beneficial effects against ASM remodeling are lost once the disease is established. Uniquely, we show that anti-IL-33 ameliorates rhinovirus-induced exacerbation by suppressing type 2 inflammation, restoring antiviral immunity, increasing viral clearance, and decreasing alarmin expression in the bronchial epithelium. Our findings in vivo were replicated in vitro by using human AECs from healthy subjects and asthmatic patients infected with rhinovirus. Anti-IL-33 boosted antiviral immunity in cells from both healthy subjects and asthmatic patients and controlled viral burden. Monoclonal antibodies targeting IL-33 or its receptor have now entered phase I trials. With phase II trials on the horizon, it will be important to take the opportunity to assess whether 
METHODS

Virus and allergen-coinduced asthma and rhinovirus-induced exacerbation
Specific pathogen-free BALB/c mice were inoculated intranasally at 7 days of age with 1 pfu of PVM (strain J3666) E1 or vehicle (Dulbecco modified Eagle medium plus 10% FCS) after achievement of light isoflurane-induced anesthesia. Mice were reinoculated 6 weeks later (49 days old) with 20 pfu of PVM or vehicle diluent. Mice were exposed intranasally to 1 mg of CRE allergen (Greer Laboratories) or vehicle at 10 and 52, 59, 66, and 73 days of age, as indicated, and killed at 76 days of age. E2 Anti-IL-33 or isotype control antibody (200 mg; Pfizer) or dexamethasone (75 mg; Sigma-Aldrich) was administered, according to the study design. For rhinovirus exacerbation, mice were rested for 4 weeks after the final CRE challenge and then inoculated with RV-1B (5 3 10 6 TCID 50 ) intranasally. All studies were approved by the University of Queensland Animal Ethics Committee.
Sample extraction and processing
After euthanasia by means of pentobarbitone overdose, bronchoalveolar lavage was performed with 600 mL of PBS. BALF was centrifuged at 5000 rpm at 48C for 5 minutes, and the supernatant was stored at 2808C until analysis by using a cytokine bead array or ELISA. BALF cells were analyzed immediately by using flow cytometry. Lung lobes were excised and processed, as previously described. E3 Briefly, the left lung lobe was processed immediately for flow cytometry, and the superior right lobe was fixed in 10% formalin neutral buffer overnight before storage in 70% ethanol. The postcaval and inferior lobes were pooled and snap-frozen before mechanical digestion and clarification, followed by analysis by means of ELISA. The inferior right lobe was snap-frozen before RNA extraction. All snap-frozen lungs were stored at 2808C.
Flow cytometry
Flow cytometry was performed on BALF cells or lung tissue digest cells, as previously described. E3 Briefly 
Immunohistochemistry
Paraffin-embedded lung sections were prepared, as previously described.
E1
For immunohistochemistry, lung sections were pretreated with 10% normal goat serum for 30 minutes. Sections were probed with anti-IL-33 (AF3626; R&D Systems), anti-HMGB1 (Ab 18256; Abcam, Cambridge, United Kingdom), anti-pro-SPC (Millipore, Temecula, Calif), anti-a-smooth muscle actin (Sigma-Aldrich), and anti-Muc5ac (Thermo Fisher) overnight at 48C. 
Measurement of protein expression
The limit of detection for each assay is indicated in parentheses: IL-33 (R&D Systems; 15 pg/mL), IL-25 (BioLegend; 1 pg/mL), HMGB1 (Chondrex, Redmond, Wash; 0.5 ng/mL), and IL-5 (BD Biosciences; 9 pg/mL) expression was quantified by means of ELISA. IL-13 (Enhanced Sensitivity Flex Set; BD Biosciences; 9 fg/mL) expression was quantified by using the cytokine bead array.
Quantitative real-time PCR
Total RNA was isolated from the inferior right lung lobe with TriReagent solution (Ambion), followed by phenol-chloroform extraction. DNAse digestion was performed with Turbo DNAse (Ambion), according to the manufacturer's instructions. Reverse transcription was performed with M-MLV reverse transcriptase and random primers (Invitrogen). Quantitative real-time PCR was performed with SYBR Green (Life Technologies, Grand Island, NY) with the primers described in Table E1 . RV-1B or RV-16 viral copy numbers were determined by generating a standard curve of RV-1B or RV-16 viral copies. Expression values were normalized to Hprt or Actb and expressed as fold change over vehicle-treated mice or cells, as previously described.
E1,E2
Statistical analyses
GraphPad Prism version 5.0 software was used for all statistical analyses. The Student t test, 1-way ANOVA with a Tukey post hoc test, or 2-way ANOVA with the Sidak post hoc test was applied as appropriate. A P value of less than .05 was considered statistically significant. (Fig E1, B) and neutrophils (Fig E1, C) in BALF. D, Muc5ac score. E, ASM area. F, Study design. Mice were killed 4 days after C1 (49 DPI). G and H, Eosinophils (Fig E1, G) and neutrophils (Fig E1, H) in BALF. I, Muc5a score. J, ASM area. *Significance compared with vehicle-treated mice. #Significance compared with 45 DPI CRE mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 4-8 mice per group) representative of 2 experiments. **P < .01 and ***P < .001. ##P < .01 and ###P < .001.
FIG E2
. IL-33 blockade during the progression and chronic phases. Mice were treated per the study design in Fig 1, A. A, Total BALF cells. B and C, Lymphocytes (Fig E2, B) and mononuclear (Fig E2, C) cells in BALF. *Significance compared with vehicle-treated mice. #Significance compared with-isotype treated mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 5-8 mice per group) representative of 2 experiments. **P < .01 and ***P < .001. Dex, Dexamethasone; Iso, isotype; Veh, vehicle.
FIG E3
. IL-33 blockade during the chronic phase alone. Mice were treated per the study design in Fig 2, A. A, Total BALF cells. B and C, Lymphocytes (Fig E3, B) and mononuclear cells (Fig E3, C) in BALF. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 6-8 mice per group) representative of 2 experiments. *P < .05, **P < .01, and ***P < .001. #P < .05. Dex, Dexamethasone; Iso, isotype; Veh, vehicle. (Fig E4, A) and IL-25 (Fig E4, B) in BALF of vehicle-treated mice infected with RV-1B alone. C, Total BALF cells. D and E, Lymphocytes (Fig E4, D) and mononuclear cells (Fig E4, E) in BALF. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice. Box and whisker plots show quartiles (boxes) and range (whiskers; n 5 6-9) representative of 2 experiments. ***P < .001. #P < .05 and ###P < .001. DPI, Days postinfection; Veh, vehicle.
FIG E5
. IL-33 blockade during a rhinovirus (RV) exacerbation. Mice were treated per the study design in Fig 5, A. A, Total BALF cells. B and C, Lymphocytes (Fig E5, B) and mononuclear cells (Fig E5, C) in BALF. *Significance compared with vehicle-treated mice. #Significance compared with isotype-treated mice. Data are means 6 SEMs (n 5 7-9 mice per group) representative of 2 experiments. **P < .01 and ***P < .001. #P < .05 and ###P < .001. 
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